	US 12,410,249 B2
	Low dose antibody-based methods for treating hematologic malignancies
Dragan Cicic, Brooklyn, NY (US)
Assigned to Actinium Phamaceuticals, Inc., New York, NY (US)
Filed by Actinium Pharmaceuticals, Inc., New York, NY (US)
Filed on Feb. 24, 2022, as Appl. No. 17/679,213.
Application 17/679,213 is a continuation of application No. 16/300,672, granted, now 11,292,835, previously published as PCT/US2017/034406, filed on May 25, 2017.
Claims priority of provisional application 62/342,568, filed on May 27, 2016.
Prior Publication US 2022/0251196 A1, Aug. 11, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 51/10 (2006.01); A61P 35/02 (2006.01)

CPC C07K 16/2803 (2013.01) [A61K 51/1069 (2013.01); A61K 51/1093 (2013.01); A61K 51/1096 (2013.01); A61P 35/02 (2018.01); A61K 2039/505 (2013.01)]

13 Claims

1. A method for treating relapsed and/or refractory acute myeloid leukemia in a human subject, comprising the step of:

intravenously administering a therapeutically effective dose of ²²⁵Ac-labeled HuM195 to a human subject afflicted with relapsed and/or refractory acute myeloid leukemia, wherein the human subject has a peripheral blast burden below 200 blast cells/μl.